CVR - Coronavirus Vaccines R&D Roadmap

Milestone
3.3.a

Harmonized endpoints

Not started

Develop a set of harmonized clinical end points—such as infection, severe disease, death, and potentially long COVID/PASC— and immunologic end points that can be used in vaccine efficacy studies for coronavirus vaccines to demonstrate protection against SARS-CoV-2 variants and “common cold” coronaviruses.